September 16, 2024
As the pharmaceutical landscape in the Japan and Asia-Pacific (JAPAC) region continues to evolve, the demand for efficient, high-quality medical information (MI) services has never been greater. Our offshore contact centers in India and the Philippines offer pharmaceutical companies an unparalleled blend of innovation, customer excellence, and cost efficiency. With years of experience and a proven track record, our offshore solutions are designed to meet the specific needs of the JAPAC market, whether through fully integrated offshore services or hybrid models that combine the best of both worlds.
In this blog, we delve into the advantages of utilizing offshore contact centers and highlight the successful models we’ve implemented with our clients, delivering robust, compliant, and scalable MI services.
We’re uniquely positioned to help clients transition their MI services to a model that leverages the strengths of offshore contact centers in India and the Philippines. Whether through a hybrid approach that combines ANZ-based services with offshore support or a fully offshore solution, our extensive experience ensures a seamless transition without compromising service quality. Our team of specialists are committed to customer excellence, scalability, flexibility, and cost efficiency.
With ProPharma, you can trust that your MI services are in capable hands, enabling you to focus on what matters most—delivering innovative healthcare solutions to the world.
Ready to access 25 years of world-class medical information expertise?Contact us today!
TAGS: Medical Information Australia Asia
November 13, 2013
In the just issued Johnson & Johnson Corporate Integrity Agreement (CIA), the Office of Inspector General (OIG) has, for the second time in less than a year, required that a company maintain a...
May 30, 2019
At the beginning of each federal fiscal year, the US FDA posts the previous year's Form 483 observation metrics issued by each product center. Inspections ending between 10/1/2017 and 9/30/2018, for...
January 10, 2018
At the beginning of each federal fiscal year, the US FDA posts the previous year’s Form 483 observation metrics issued by each product center. I find that reviewing these metrics provides a valuable...